

 
 
Retired Policy 
 
Tumor-Informed    and    Tumor-Agnostic    (Plasma-Only) 
Circulating Tumor DNA Minimal Residual Disease (MRD) 
Detection for Cancer Management  
 
Policy #     00792 
Original Effective Date: 07/11/2022 
Retired Date: 07/01/2024 
 
 
 Â©2024 Blue Cross and Blue Shield of Louisiana 
 
Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and 
incorporated as Louisiana Health Service & Indemnity Company. 
 
No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, 
electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana. 
 
Page 1 of 1 
 
Tumor-Informed  and  Tumor-Agnostic  (Plasma-Only)  Circulating  Tumor  DNA  Minimal  Residual 
Disease (MRD) Detection for Cancer Management was retired effective 07/01/2024. 
 
A retired medical policy is no longer active and is not utilized for coverage eligibility determination 
or claims processing as of the retired date. 
 
This medical policy is being retired  as a part of the collaborative partnership with Carelon MBM 
Genetic  Testing  Program.   Carelon will  provide genetic testing  management  services  to  ensure 
enforcement of genetic testing policies effective 07/01/2024. 
 
 